The “Gotong Royong” or “Mutual Cooperation” vaccine program has been confirmed using the Sinopharm vaccine.
This determination is based on the Minister of Health Decree Number HK.01.07 / MENKES / 4643/2021 concerning Determination of the Purchase Price of Sinopharm Vaccines through the Appointment of State-Owned PT Bio Farma in the Implementation of Procurement of Covid-19 Vaccines and Maximum Service Rates for Mutual Cooperation Vaccines.
In this Ministerial Decree, determining the purchase price for the vaccine produced by Sinopharm through the appointment of PT Bio Farma in the implementation of the procurement of the Covid-19 vaccine and the maximum service tariff for the implementation of mutual cooperation vaccinations is as follows:
1. The purchase price of the vaccine is IDR 321,660 per dose; and
2. The maximum tariff for vaccination services is Rp. 117,910 per dose
This price is the highest price of vaccine per dose purchased by a legal entity or business entity, including profit (Max. 20%) and distribution costs.
The figure was determined after obtaining input from various parties, including the Coordinating Ministry for Economic Affairs, experts, academics, and legal officials.
As for the maximum tariff for vaccination services, the government sets a price of Rp. 117,910 per dose.
The Sinopharm vaccine is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell).
The vaccine uses dead viral particles to expose the immune system to the virus, without risking a serious disease response.
The Covid-19 vaccine made by Sinopharm has been declared safe by the Food and Drug Supervisory Agency (BPOM) and has received a halal certificate from the Indonesian Ulema Council (MUI).
BPOM issued an emergency use authorization (EUA) for the Sinopharm vaccine on April 29, 2021.
For the procurement of vaccines, the government has entered into a contract for Sinopharm vaccine procurement of 7.5 million doses, with the number of vaccines available up to 500 thousand doses.
Head of BPOM Penny K Lukito said, based on the results of clinical trials conducted in the United Arab Emirates, it was found that the Sinopharm vaccine had 78% efficacy.
“Phase III clinical studies conducted in the United Arab Emirates involving about 42,000 volunteers showed the efficacy of the vaccine was 78%,” said Penny in a virtual press conference late last month.
In addition, Penny said, the post-immunization effects (AEFI) caused by the Sinopharm vaccine was mild, includint swelling, redness, headache, diarrhea, muscle pain, or coughing.
“So from the safety aspect it is good and well tolerated,” he said.
The World Health Organization (WHO) also recommends giving the Sinopharm vaccine to adults aged 18 years and over in two injection doses.
The interval between the first dose and the second dose is recommended between three to four weeks.
Apart from Sinopharm, the government has also prepared 5 million doses of the Covid-19 vaccine produced by CanSino Biologics, China in this mutual cooperation vaccination program.
In contrast to Sinopharm, the CanSino vaccine is only given in one injection dose.